EUVIMEDEUVIMED entdecken
Crossref

Diagnostic and therapeutic recommendations of the Polish Society of Haematologists and Transfusiologists and Polish Adult Leukemia Group-CLL for chronic lymphocytic leukemia in 2021

Iwona Hus, Krzysztof Giannopoulos, Krzysztof Jamroziak, Jerzy Błoński, Dariusz Wołowiec, Jacek Roliński, Piotr Smolewski, Tadeusz Robak

Hematology in Clinical Practice · 2021

DOI: 10.5603/hcp.2021.0001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hematology in Clinical Practice, 2021. Verfasst von Iwona Hus und 7 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic lymphocytic leukemia (CLL) is a disease of the elderly, with a median age at diagnosis of approximately 70 years. The natural course of the disease varies greatly, and patients with nonprogressive and asymptomatic leukemia do not require treatment. The results of CLL treatment have improved significantly in recent years, mainly due to the introduction of new, more effective drugs, including BCR inhibitors and BCL2 inhibitors. The new drugs are used continuously, while venetoclax in combination with anti-CD20 antibodies is used for 24 (rituximab) or 12 (obinutuzumab) months, depending on the type of antibody and line of therapy. The choice of treatment protocol should largely depend on the assessment of 17p deletion/TP53 mutation and immunoglobulin variable heavy chain (IGVH) mutation status, which correlate with a worse response to immunochemotherapy. The role of immunochemotherapy, which until recently was the mainstay of CLL treatment, has now significantly decreased. In the first-line, it is recommended only in patients without 17p deletion/TP53 mutation, with mutated IGVH. Other patients should receive novel targeted therapies. However, at the time of the preparation of these recommendations, these therapies are not available in the firs-line of treatment in Poland. Novel targeted therapies play a major role in the treatment of refractory/relapsed CLL, and immunochemotherapy is recommended primarily in patients with a long-term response to first-line therapy. In this article, we present an update of the guidelines for the diagnosis and treatment of CLL, including the treatment of autoimmune complications, as well as the prophylaxis and treatment of infections, developed by the Polish Society of Haematologists and Transfusiologists and PALG-CLL Working Group.

Zitieren

APA

Hus, I., Giannopoulos, K., Jamroziak, K., Błoński, J., Wołowiec, D., Roliński, J., Smolewski, P., & Robak, T. (2021). Diagnostic and therapeutic recommendations of the Polish Society of Haematologists and Transfusiologists and Polish Adult Leukemia Group-CLL for chronic lymphocytic leukemia in 2021. Hematology in Clinical Practice. https://doi.org/10.5603/hcp.2021.0001

Vancouver

Hus I, Giannopoulos K, Jamroziak K, Błoński J, Wołowiec D, Roliński J, et al. Diagnostic and therapeutic recommendations of the Polish Society of Haematologists and Transfusiologists and Polish Adult Leukemia Group-CLL for chronic lymphocytic leukemia in 2021. Hematology in Clinical Practice. 2021. doi:10.5603/hcp.2021.0001

BibTeX
@article{Hus2021,
  author = {Hus, Iwona and Giannopoulos, Krzysztof and Jamroziak, Krzysztof and Błoński, Jerzy and Wołowiec, Dariusz and Roliński, Jacek and Smolewski, Piotr and Robak, Tadeusz},
  title = {Diagnostic and therapeutic recommendations of the Polish Society of Haematologists and Transfusiologists and Polish Adult Leukemia Group-CLL for chronic lymphocytic leukemia in 2021},
  journal = {Hematology in Clinical Practice},
  year = {2021},
  doi = {10.5603/hcp.2021.0001}
}
Kostenlos starten →